Researchers at ASH shared Phase III data comparing the pre- and five-year post-treatment adjusted annualized bleeding rates, ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...

The firm said it is planning a regulatory filing with the European Medicines Agency next year to begin clinical studies of PCT1:CO-STIM.

As part of the trial, investigators will initially evaluate ARO-MAPT in up to 64 healthy subjects, followed by up to 48 Alzheimer's disease patients.

Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.

At the meeting, researchers shared real-world data showing ctDNA positivity at the end of treatment was prognostic across lymphoma subtypes and better than PET scans.